| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | -1352.20% | — |
| EBITDA Margin | — | — | — | — | — | — | — | -1349.20% | — |
| Net Margin | — | — | — | — | — | — | — | -1146.80% | — |
| Current Ratio | 11.81 | 8.28 | 19.27 | 15.61 | 29.82 | 13.77 | 6.70 | 13.87 | 1.49 |
| Quick Ratio | 11.81 | 8.28 | 19.27 | 15.61 | 29.82 | 13.77 | 6.70 | 13.87 | 1.49 |
| Debt / Equity | — | — | — | — | — | — | — | — | — |
| ROE | -58.39% | -60.03% | -37.96% | -42.97% | -30.87% | -47.25% | -139.81% | -33.68% | -533.17% |
| ROA | -53.39% | -52.74% | -35.78% | -39.76% | -29.84% | -43.75% | -117.63% | -31.27% | -236.40% |
| Asset Turnover | — | — | — | — | — | — | — | 0.03 | — |
| Book Value / Share | 1.19 | 1.01 | 1.57 | 1.20 | 2.12 | — | — | 2.20 | — |
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing innovative therapies for serious vascular diseases driven by restricted blood flow and endothelial dysfunction. Its lead candidate, DM199, is a recombinant form of the human tissue KLK1 protein, designed to enhance blood flow and vascular health by increasing levels of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor. The company focuses on advancing DM199 for the treatment of preeclampsia, fetal growth restriction, and acute ischemic stroke, with ongoing clinical programs including Phase 2 investigator-sponsored trials and the ReMEDy2 Phase 2/3 trial. DiaMedica Therapeutics Inc. also explores applications in chronic kidney disease. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company engages in clinical development, regulatory interactions, and corporate activities to address unmet needs in these critical therapeutic areas.